Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott Boosts Diagnostics Arm With Alinity H-Series Launch
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
Abbott (ABT) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
by Zacks Equity Research
Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.
Global In Vitro Diagnostic Market Booms: Stocks in Focus
by Zacks Equity Research
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
DexCom-Lily Partnership to Boost CGM Platform, Customer Base
by Zacks Equity Research
DexCom (DXCM) continues to sign deals to boost CGM platform adoption.
HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View
by Zacks Equity Research
HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.
Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on its Roto-Rooter business in Q3
ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines
by Zacks Equity Research
ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Stryker (SYK) posted strong numbers in the third quarter owing to higher revenues.
Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y
by Zacks Equity Research
Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.
Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.
GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down
by Zacks Equity Research
GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.
Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up
by Zacks Equity Research
Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.
McKesson (MCK) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance
by Zacks Equity Research
Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.
Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.
Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up
by Zacks Equity Research
Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
by Zacks Equity Research
NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.